Published in Value Health on October 23, 2009
The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genet Med (2014) 1.68
Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda. PLoS One (2015) 1.38
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Economic evaluation of task-shifting approaches to the dispensing of anti-retroviral therapy. Hum Resour Health (2012) 0.87
Economic analysis of complementary, alternative, and integrative medicine: considerations raised by an expert panel. BMC Complement Altern Med (2013) 0.86
Examining the impact of genetic testing for type 2 diabetes on health behaviors: study protocol for a randomized controlled trial. Trials (2012) 0.83
Approaches to identifying, measuring, and aggregating elements of value. Int J Technol Assess Health Care (2013) 0.79
Economic evaluation of vaccines in Canada: A systematic review. Hum Vaccin Immunother (2016) 0.76
Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States. Transplantation (2016) 0.76
Beyond AWP . . . way beyond. Value Health (2009) 0.76
Dynamics in the costs of criminality among opioid dependent individuals. Drug Alcohol Depend (2014) 0.76
The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008. Rheumatol Int (2013) 0.75
Role of Health Services Research in Producing High-Value Rehabilitation Care. Phys Ther (2015) 0.75
What's in a perspective? Value Health (2009) 0.75
The costs of crime during and after publicly-funded treatment for opioid use disorders: a population-level study for the state of California. Addiction (2016) 0.75
US-Based Drug Cost Parameter Estimation for Economic Evaluations. Med Decis Making (2014) 0.75
Estimating development cost of an interactive website based cancer screening promotion program. Eval Program Plann (2015) 0.75
Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors. BMC Cancer (2016) 0.75
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med (2014) 5.01
Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med (2004) 3.93
Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res (2004) 3.37
Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm (2003) 3.34
Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health (2013) 2.82
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA (2003) 2.50
Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care (2003) 2.33
Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med (2011) 2.12
Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA). J Bone Miner Res (2004) 1.76
Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis (2004) 1.65
Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res (2002) 1.58
An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med (2004) 1.48
Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther (2004) 1.46
Where's the value in health care? Value Health (2006) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale? Med Decis Making (2002) 1.28
Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm (2006) 1.26
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. Health Qual Life Outcomes (2003) 1.17
Evaluation and management of osteoporosis following hospitalization for low-impact fracture. J Gen Intern Med (2003) 1.16
Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis. Health Aff (Millwood) (2007) 1.12
Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health (2009) 1.11
Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health (2003) 1.09
Evaluating the cost-effectiveness of statins. J Manag Care Pharm (2004) 1.08
The National Program of Cancer Registries: explaining state variations in average cost per case reported. Prev Chronic Dis (2005) 1.02
Colorectal cancer screening attitudes and practices in the general population: a risk-adjusted survey. J Public Health Manag Pract (2005) 1.00
Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health (2009) 0.98
Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood) (2008) 0.98
Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care (2003) 0.96
Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health (2009) 0.96
Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health (2009) 0.96
Evaluation of three population-based strategies for fracture prevention: results of the osteoporosis population-based risk assessment (OPRA) trial. Med Care (2005) 0.95
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause (2003) 0.95
Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol (2004) 0.94
Study protocol: the Back Pain Outcomes using Longitudinal Data (BOLD) registry. BMC Musculoskelet Disord (2012) 0.94
Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care (2003) 0.91
Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr (2013) 0.88
Study protocol- Lumbar Epidural steroid injections for Spinal Stenosis (LESS): a double-blind randomized controlled trial of epidural steroid injections for lumbar spinal stenosis among older adults. BMC Musculoskelet Disord (2012) 0.88
Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. Am J Health Syst Pharm (2007) 0.87
Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry (2011) 0.87
The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol (2013) 0.87
Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care (2012) 0.86
Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf (2012) 0.85
Costs and benefits of male circumcision. JAMA Pediatr (2013) 0.85
Management of osteoporosis in women aged 50 and older with osteoporosis-related fractures in a managed care population. Dis Manag (2003) 0.84
Back pain in seniors: the Back pain Outcomes using Longitudinal Data (BOLD) cohort baseline data. BMC Musculoskelet Disord (2014) 0.83
Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol (2008) 0.83
Evaluation of decision rules to identify postmenopausal women for intervention related to osteoporosis. Dis Manag (2003) 0.83
Compulsive cell phone use and history of motor vehicle crash. J Adolesc Health (2013) 0.82
Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. Clin Ther (2005) 0.81
Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics (2013) 0.80
The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin (2004) 0.80
Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections? Am Surg (2005) 0.80
A Markov decision process approach to multi-category patient scheduling in a diagnostic facility. Artif Intell Med (2011) 0.80
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother (2007) 0.79
A Cost Minimization Comparison of Two Surfactants-Beractant and Poractant alfa-Based Upon Prospectively Designed, Comparative Clinical Trial Data. J Pediatr Pharmacol Ther (2004) 0.79
Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. J Infect Dis (2011) 0.79
Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm (2005) 0.79
Endogeneity bias in the absence of unobserved heterogeneity. Ann Epidemiol (2004) 0.79
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol (2012) 0.78
Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer (2009) 0.78
Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther (2012) 0.77
Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits. Acad Radiol (2012) 0.77
Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement. Acad Radiol (2011) 0.76
Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs (2005) 0.76
Exploratory economic evaluation of patients with COPD on a combination product versus individual components (ipratropium bromide and albuterol). Adv Ther (2007) 0.76
Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent (2010) 0.76
Symptom control and improved functioning: the effect of omalizumab on asthma-related quality of life (ARQL). J Asthma (2005) 0.76
Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One (2013) 0.76
Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ (2012) 0.76
Expensive conditions. Health Aff (Millwood) (2002) 0.75
Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy (2006) 0.75
Effects of medicaid on clinical outcomes. N Engl J Med (2013) 0.75
A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol (2008) 0.75
What is more valuable: fenofibrate patents or fenofibrate clinical outcomes? Arch Intern Med (2012) 0.75
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS Drugs (2015) 0.75
Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm (2015) 0.75
Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ (2013) 0.75
A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics (2014) 0.75
Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine (2013) 0.75
Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75